Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

Funder: National Cancer Institute

Funding period
USD 703 K
Funding amount
Abstract
Immune checkpoint inhibition (CPI) with anti-PD-1/PD-L1 antibodies has changed the treatment landscape for several types of cancers including bladder cancer. In patients with advanced bladder cancer, CPI can induce unprecedented durable responses. However, only a subset of patients responds to such treatment necessitating a better understanding of mechanisms of primary resistance to facilitate the identification of predictive biomarkers and rational combination approaches. We used an integrative approach to identify biomarkers in a large clinical trial cohort of patients with metastatic bladder cancer that are independently associated with response/resistance to CPI beyond tumor mutational burden (TMB) alone. We identified three key gene modules derived from pre-treatment tumor transcriptomic data: a ?good immune? module associated with response to CPI, a stromal module associated with resistance to CPI, and a ?bad immune? module also associated with resistance to CPI, but that appears to mediate the negative impact of the stromal module upon outcomes with CPI. Using single cell RNA sequencing data generated from fresh bladder cancer specimens to dissect the cellular components and molecular interactions responsible for expression of these 3 gene modules, we determined that the ?good immune? module emanates largely from T- cells and NK cells, the stromal module emanates from cancer-associated fibroblasts (CAFs), and the ?bad immune? module emanates predominantly from monocytes-macrophages (M?). We hypothesize that myeloid cells drive primary resistance to CPI in bladder cancer. We further hypothesize that comprehensive cellular and molecular maps of bladder cancer will facilitate identification of precise monocyte-M? subpopulations, and CAF-myeloid-T-cell interactions, that can be leveraged to define novel biomarkers and therapeutic targets. With access to a unique set of clinical trial cohorts that will provide tumor tissue, blood and urine specimens as well as outcome data to CPI, we are uniquely positioned to: (Aim 1) Dissect gene modules associated with response/resistance to CPI using high resolution maps of the cellular and molecular landscape of muscle-invasive bladder cancer; Aim 2: Define the role of ?bad immune? module genes in governing monocyte-M?-mediated immune suppression; Aim 3: Refine and validate a monocyte-M?-related gene signature as a biomarker of CPI resistance in clinical trial cohorts. This proposal comprises an integrated network of multi-disciplinary collaborative investigators (GU oncologists, urologists, immunologists and bioinformaticians) to accelerate translational research and maximize future clinical benefits. These efforts will lead to the discovery of biomarkers, and potential therapeutic targets, to extend the benefits of CPI beyond the 15-20% of patients with advanced bladder cancer that respond to treatment.
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Human Genome

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science